Valuation: Akeso, Inc.

Capitalization 99.36B 111B 14.24B 12.24B 11.41B 10.6B 19.79B 1,286B 21.34B 131B 51.55B 615B 53.41B 52.32B 2,267B P/E ratio 2025 *
-449x
P/E ratio 2026 * 129x
Enterprise value 96.06B 107B 13.77B 11.83B 11.03B 10.25B 19.13B 1,244B 20.63B 127B 49.84B 594B 51.64B 50.58B 2,192B EV / Sales 2025 *
28.6x
EV / Sales 2026 * 17.6x
Free-Float
74.46%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
12-11 Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab CI
12-10 Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025 CI
12-09 Akeso, Inc. Announces Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia Congress CI
12-09 Akeso, Inc. Announces Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia CI
11-17 Akeso, Inc.'s Bispecific Antibody Targeting Aß and BBB-Expressed Receptor Approved for Alzheimer's Disease Clinical Trials in China CI
11-10 Akeso announces first patient dosed in Phase I trial of personalized mRNA vaccine AK154 as monotherapy or in combination with Cadonilimab or Ivonescimab RE
11-10 Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer CI
11-07 Akeso, Inc. Unveils Promising Preclinical Data for IL-1RAP Targeting Antibody At SITC 2025 CI
11-07 Akeso Announces Final OS Analysis Results Of Ivonescimab HARMONi-A Study At SITC 2025 CI
11-03 Akeso's Ivonescimab Secures Fourth Breakthrough Therapy Designation in China for First-Line Treatment of Triple-Negative Breast Cancer CI
25-10-31 Summit Therapeutics Inc. Announces Results from the Phase III Harmoni-A Trial, Conducted in China and Sponsored by Akeso, Inc CI
25-10-20 Akeso's Ivonescimab Shows Strong Phase 3 Results in Lung Cancer Trial MT
25-10-19 Akeso Announces Results of the Registrational Phase III Clinical Study Evaluating Ivonescimab (PD-1/VEGF Bispecific Antibody) CI
More news
1 day-4.36%
1 week+2.99%
Current month+6.73%
1 month-3.13%
3 months-4.74%
6 months+2.03%
Current year+6.73%
More quotes
1 week 116
Extreme 116
130.5
1 month 108
Extreme 108
130.5
Current year 111
Extreme 111
130.5
1 year 54
Extreme 54
179
3 years 26.45
Extreme 26.45
179
5 years 11.5
Extreme 11.5
179
10 years 11.5
Extreme 11.5
179
More quotes
Manager TitleAgeSince
Corporate Officer/Principal 50 2019-11-15
Corporate Officer/Principal 57 2019-11-15
Chief Tech/Sci/R&D Officer 58 2019-11-15
Director TitleAgeSince
Chairman 59 2012-03-18
Director/Board Member 58 2019-11-15
Director/Board Member 57 2019-11-15
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-4.36%+2.99%+117.69%+162.46% 14.9B
+3.75%+1.96%+7.76%+89.61% 48.01B
+6.00%+10.61%+96.03%+15.05% 41.97B
-3.17%-6.93%+136.38%+737.74% 35.77B
+4.36%+8.86%-6.12%-26.38% 25.64B
-0.74%+6.77%+37.30%-21.62% 20.81B
+5.85%+18.68%+135.38%-41.71% 19.92B
-2.44%-10.93%-8.56%+246.25% 13.14B
-1.68%+11.30%+185.68% - 14.63B
+0.50%+1.47%+25.55%+169.75% 11.86B
Average +0.82%+4.84%+72.71%+147.90% 24.67B
Weighted average by Cap. +1.70%+3.68%+69.97%+159.61%
See all sector performances

Financials

2025 *2026 *
Net sales 3.35B 3.75B 481M 413M 385M 358M 668M 43.42B 720M 4.43B 1.74B 20.75B 1.8B 1.77B 76.52B 5.38B 6.02B 771M 663M 618M 574M 1.07B 69.65B 1.16B 7.1B 2.79B 33.29B 2.89B 2.83B 123B
Net income -204M -228M -29.21M -25.1M -23.41M -21.75M -40.58M -2.64B -43.76M -269M -106M -1.26B -110M -107M -4.65B 771M 863M 111M 95.02M 88.6M 82.33M 154M 9.99B 166M 1.02B 400M 4.77B 415M 406M 17.6B
Net Debt -3.3B -3.69B -473M -407M -379M -352M -658M -42.75B -709M -4.36B -1.71B -20.43B -1.78B -1.74B -75.35B -4.78B -5.35B -686M -589M -550M -511M -953M -61.95B -1.03B -6.32B -2.48B -29.6B -2.57B -2.52B -109B
More financial data * Estimated data
Logo Akeso, Inc.
Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.
Employees
3,529
More about the company
Date Price Change Volume
26-01-13 120.60 $ -4.36% 14,510,218
26-01-12 126.10 $ -1.18% 7,169,029
26-01-09 127.60 $ -0.47% 4,644,895
26-01-08 128.20 $ -0.77% 4,841,419
26-01-07 129.20 $ +7.31% 11,429,410

Delayed Quote Hong Kong S.E., January 13, 2026 at 03:08 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
107.85CNY
Average target price
154.69CNY
Spread / Average Target
+43.43%
Consensus

Quarterly revenue - Rate of surprise